Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 4D Molecular Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-275.04 Mil. 4D Molecular Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $478.75 Mil. Therefore, 4D Molecular Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -57.45%.
The historical rank and industry rank for 4D Molecular Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
FDMT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -61.82 Med: -38.23 Max: -24.78
Current: -36.29
During the past 9 years, 4D Molecular Therapeutics's highest Return-on-Tangible-Equity was -24.78%. The lowest was -61.82%. And the median was -38.23%.
FDMT's Return-on-Tangible-Equity is ranked better than 53.08% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs FDMT: -36.29
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
4D Molecular Therapeutics Return-on-Tangible-Equity Related Terms
4D Molecular Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for 4D Molecular Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FDMT vs TECX, ACHV, STTK: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, 4D Molecular Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -57.45% mean?
4D Molecular Therapeutics (FDMT) has a Return-on-Tangible-Equity of -57.45% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 4D Molecular Therapeutics and its competitors. According to the industry distribution chart, 4D Molecular Therapeutics ranks #563 out of 1200 companies in the Biotechnology industry, placing it in the top 46.9%.
Is 4D Molecular Therapeutics' Return-on-Tangible-Equity too high?
4D Molecular Therapeutics' current Return-on-Tangible-Equity is -57.45%. Based on the distribution chart, 4D Molecular Therapeutics ranks #563 out of 1200 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Return-on-Tangible-Equity compare to TECX and ACHV?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #563 out of 1200 companies for Return-on-Tangible-Equity. This puts 4D Molecular Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current Return-on-Tangible-Equity is -57.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $215.03, compared to a current price of $13.32 — trading 93.8% below its estimated fair value. The current Return-on-Tangible-Equity is -57.45%. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Return-on-Tangible-Equity is -57.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?
Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued.
The current stock price of $13.32 is trading 93.8% below its estimated GF Value™ of $215.03.
GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.
Key valuation signals for FDMT:
Return-on-Tangible-Equity: -57.45%
GF Value™: $215.03 vs. price of $13.32 (93.8% below fair value)
No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score
Get the complete analysis for FDMT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMT has been successfully added to your 
